Advances in the Development of Prophylactic and Therapeutic Cancer Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 38
Special Issue Editors
Interests: cancer; infectious diseases; vaccine; vaccine adjuvants; prophylactic; therapeutic; immunity
Interests: cancer; infectious diseases; vaccine; vaccine adjuvants; prophylactic; therapeutic; immunity
Special Issue Information
Dear Colleagues,
Our knowledge and understanding of the tumor microenvironment and tumor immunity, dictated by the direct roles of tumor cells and immune cells, have expanded significantly over the last few decades. Consequently, oncology and immunotherapy have witnessed unprecedented progress in the race to develop effective therapeutic compounds, being linked to fewer immune-related adverse events compared to their previous counterparts. We have seen tremendous successes in treating cancers, from therapeutic monoclonal antibodies targeting tumor-associated or tumor-specific antigens to immune checkpoint inhibitors and antibody–drug conjugates. Yet, due to resistance development or poor response, a large number of cancer patients cannot benefit from such therapies. Impacted by the success of both prophylactic and therapeutic vaccines developed against infectious diseases, new directions for cancer treatments have garnered renewed attention in recent years, potentiating new viable compounds.
This Special Issue focuses on the role of new developments and technologies in developing prophylactic and therapeutic cancer vaccines based on B-cell or T-cell peptides, nucleic acids, cancer cells, or viral vectors, as well as their formulation, to achieve strong cancer immunity.
Dr. Joshua Tobias
Prof. Dr. Ursula Wiedermann
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- vaccine
- vaccine adjuvants
- prophylactic
- therapeutic
- immunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
